Epstein-Barr virus

The Epstein-Barr virus (EBV) — a well-established risk factor for multiple sclerosis (MS) — is able to alter the movements of infected immune cells, a new study reveals. The findings shed new light on how EBV may set the stage for MS to develop, and could potentially form…

The risk of multiple sclerosis (MS) is significantly higher in people who carry a variant of the HLA gene called HLA-E*01:01 and have a history of infectious mononucleosis (mono), the manifestation of an Epstein-Barr virus (EBV) infection, according to a study based on U.K. Biobank data. The higher…

A pair of scientists have been awarded a 2025 Breakthrough Prize in Life Sciences for their work uncovering factors that give rise to multiple sclerosis (MS), paving the way for new therapeutic developments. Sometimes referred to as the “Oscars of Science,” Breakthrough Prizes are given each year to…

In the lymph nodes of the neck of people with multiple sclerosis (MS), certain immune cells show abnormalities in activity and signs of reactions against the Epstein-Barr virus (EBV), a new study reports. The findings may help to explain the connection between MS and EBV, researchers said. The study,…

A Phase 1 clinical trial that is investigating a new vaccine against the Epstein-Barr virus (EBV), a well-established risk factor for developing multiple sclerosis (MS), in healthy volunteers has dosed its first participant. The vaccine, called MDX2201, is being developed by Modex Therapeutics, an Opko Health company,…

Using antibodies against a viral protein that’s needed for the Epstein-Barr virus (EBV) to invade human cells was found to successfully prevent viral infections and EBV-associated cancer in mice in a new study. By identifying sites where these antibodies bind to the viral protein — called gp42 — researchers…

Using a vaccine against the Epstein-Barr virus (EBV) to prevent the development of multiple sclerosis (MS) is highly likely to be cost-effective, especially when given in early adolescence, according to an Australian modeling study. “The evidence from this study highlights the urgent need for the development of an EBV…

ATA188, an experimental cell therapy targeting the Epstein-Barr virus, failed to outperform a placebo at easing disability levels in people with nonactive progressive forms of multiple sclerosis (MS), according to data from the Phase 2 portion of the EMBOLD clinical trial. The medication also showed no signs of…

New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), and explain why only some people infected with EBV — previously found to raise the risk of MS by 32 times — go on to develop the neurodegenerative disorder. Distinct…

The multiple sclerosis (MS) community is gearing up for the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, taking place this week both virtually and in San Diego, California. The yearly meeting, occurring Feb. 23-25 at the Marriott Marquis San Diego Marina, is bringing together…

Tevogen Bio has announced plans to develop T-cell therapies targeting the Epstein-Barr virus (EBV), a herpes virus known to be a major environmental risk factor for multiple sclerosis (MS). The decision comes on the heels of positive safety data from a proof-of-concept Phase 1 Tevogen trial that…

A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…

Note: This column has been updated Oct. 18, 2022, to correct the name of the cholesterol medicine the columnist uses to Pravachol.  Here are a few multiple sclerosis (MS) stories that caught my eye last week: Low cholesterol and aggressive MS progression The story “Low Cholesterol May Reflect More…

People with multiple sclerosis (MS) are significantly more likely to have antibodies against the Epstein-Barr virus (EBV) — the strongest risk factor for the disease — than healthy individuals, as well as higher levels of these antibodies, according to a Spanish study. All MS patients were positive for anti-EBV…

NexImmune is working with the National Institute of Neurological Disorders and Stroke (NINDS) to develop cell therapies for people with immunological disorders associated with certain viral infections, namely the Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1). A history of infection with EBV — mostly…

T-cells Targeting Epstein-Barr Virus at High Levels in MS Patients The evidence of a link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS) continues to mount. The current thinking is that the immune responses that fight EBV may drive the attacks against the myelin nerve coating, which is…

People with multiple sclerosis (MS) have significantly more T-cells equipped with receptors that specifically recognize the Epstein-Barr virus (EBV) than do healthy individuals, a study revealed. Notably, no such differences were detected for T-cells with receptors specifically against other viruses. These findings add to previous data highlighting EBV infection…

Epstein-Barr Virus and MS Risk: New Link to Mono Found in Study Add this study to the mounting evidence that there’s some type of association between the Epstein-Barr virus (EBV) — the virus associated with mononucleosis — and multiple sclerosis. I’ve never had mono, but several people with…

People who had infectious mononucleosis — a contagious disease for which the Epstein-Barr virus (EBV) is the leading cause — had a higher incidence of multiple sclerosis (MS) in the 10 years following diagnosis compared with individuals not diagnosed with the virus, a study found. This link was particularly…

Pasithea Therapeutics investigational multiple sclerosis vaccine, PAS002, effectively delayed disease onset and reduced disease severity in a mouse model of the neurodegenerative condition, according to data from a preclinical study. The vaccine, which is designed to promote immune tolerance to a specific myelin protein, also reduced the severity…

EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead Is this another small step toward an MS cure? AT188 is an experimental therapy designed to kill cells infected with the Epstein-Barr virus (EBV). As you probably know, researchers have found a lot of evidence that EBV is connected…

An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…

The National Institutes of Health (NIH) is joining the search for a vaccine to attack the Epstein-Barr virus (EBV). This is a big deal for people with multiple sclerosis, because carrying the virus is thought to play a significant role in the development of MS. In fact,…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

Atara Biotherapeutics has reached an agreement with Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including ATA188, an experimental therapy being investigated for the treatment of progressive multiple sclerosis (MS). Under the agreement, Fujifilm will acquire Atara’s T-Cell Operations and Manufacturing (ATOM) facility in Thousand…

COVID-19 Booster May Benefit Patients on Anti-CD20 Therapy After multiple reports of how Gilenya and anti-CD20 MS medications reduce the efficacy of the mRNA COVID-19 vaccines, here’s more evidence that a booster shot may improve that protection. The researchers report “modestly increased levels” of anti–SARS-CoV-2 antibodies after a third…

Tevogen Bio is planning to make use of its virus-fighting immune cell technology and turn it against Epstein-Barr virus (EBV), a common virus thought to greatly increase the risk of multiple sclerosis (MS). The technology employs off-the-shelf cytotoxic T-cells — a type of white blood cell that can…

Similarities between an Epstein-Barr virus (EBV) protein and a brain protein called GlialCAM may explain why EBV infection increases the risk of multiple sclerosis (MS), results from a new study show. Due to the structural resemblance of the two proteins, B-cells — a type of immune cell that is critical…

You may have heard about the research that’s just been published about the Epstein-Barr virus (EBV) and multiple sclerosis (MS). The Harvard T.H. Chan School of Public Health study reports that being infected by EBV raises the risk of developing MS by 32 times. This isn’t a small or…